Fennec Pharmaceuticals In... (FENC)
5.71
0.07 (1.24%)
At close: Jan 15, 2025, 2:14 PM
Company Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company.
Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.
The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.
Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fennec Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Sep 15, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Rostislav Raykov |
Contact Details
Address: 68 TW Alexander Drive Research Triangle Park, North Carolina United States | |
| Website | https://www.fennecpharma.com |
Stock Details
| Ticker Symbol | FENC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001211583 |
| CUSIP Number | 31447P100 |
| ISIN Number | CA31447P1009 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Rostislav Raykov | Chief Executive Officer & Director |
| Robert C. Andrade | Chief Financial Officer |
| Christiana Cioffi M.B.A. | Chief Strategy Officer |
| Dr. Pierre S. Sayad M.S., Ph.D. | Chief Medical Officer |
| Lei Fang | President of Pharstat Inc |
| Mark Gowland | Controller |
| Terry Evans | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 07, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Dec 23, 2024 | 4 | Filing |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 05, 2024 | 4 | Filing |
| Dec 04, 2024 | 4 | Filing |
| Dec 02, 2024 | 4 | Filing |
| Dec 02, 2024 | 4 | Filing |